Latest Pharma Insights
Sunshine Pharma Invests In XtalPi JV For AI/Robotics Drug Discovery
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Scrip - February 2, 2026
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Scrip - February 2, 2026
PharmAbcine Founder Calls For Post-Delisting Protections For Korean Biotechs
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Scrip - February 2, 2026
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Scrip - February 2, 2026
Pending US GRAS Rule Change Points Supplement Industry Toward More NDI Notifications
“FDA’s proposed GRAS rule would move GRAS closer to the NDI model in at least one key respect, which is mandatory notification,” says attorney Ashish Talati. Proposed rule isn’t expected to require removal of ingredients available through self-GRAS processes.
HBW Insight - February 2, 2026
“FDA’s proposed GRAS rule would move GRAS closer to the NDI model in at least one key respect, which is mandatory notification,” says attorney Ashish Talati. Proposed rule isn’t expected to require removal of ingredients available through self-GRAS processes.
HBW Insight - February 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Scrip - February 2, 2026
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Scrip - February 2, 2026
Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Scrip - February 2, 2026
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Scrip - February 2, 2026
Sunshine Pharma Invests In XtalPi JV For AI/Robotics Drug Discovery
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Scrip - February 2, 2026
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Scrip - February 2, 2026
PharmAbcine Founder Calls For Post-Delisting Protections For Korean Biotechs
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Scrip - February 2, 2026
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Scrip - February 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Scrip - February 2, 2026
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Scrip - February 2, 2026
Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Scrip - February 2, 2026
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Scrip - February 2, 2026
2025 Annual Report Spotlights CDRH High Points In Challenging Year
The US FDA device center’s new annual report found notable successes in 2025 that included continuing to meet user fee goals as well as making progress on patient safety, innovation, and regulatory science.
Medtech Insight - January 30, 2026
The US FDA device center’s new annual report found notable successes in 2025 that included continuing to meet user fee goals as well as making progress on patient safety, innovation, and regulatory science.
Medtech Insight - January 30, 2026
Medtech Companies Seek More Device Input Into EU’s Cardiovascular Disease Plan
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
Medtech Insight - January 30, 2026
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
Medtech Insight - January 30, 2026
The EU Needs A System That Learns Progressively Instead Of Swinging The Pendulum
If medtech regulation is to work for patients, industry and society, Europe must move from political positioning to evidence-driven policymaking. It is time to avoid repeating the self-destructive cycle.
Medtech Insight - January 30, 2026
If medtech regulation is to work for patients, industry and society, Europe must move from political positioning to evidence-driven policymaking. It is time to avoid repeating the self-destructive cycle.
Medtech Insight - January 30, 2026
Pending US GRAS Rule Change Points Supplement Industry Toward More NDI Notifications
“FDA’s proposed GRAS rule would move GRAS closer to the NDI model in at least one key respect, which is mandatory notification,” says attorney Ashish Talati. Proposed rule isn’t expected to require removal of ingredients available through self-GRAS processes.
HBW Insight - February 2, 2026
“FDA’s proposed GRAS rule would move GRAS closer to the NDI model in at least one key respect, which is mandatory notification,” says attorney Ashish Talati. Proposed rule isn’t expected to require removal of ingredients available through self-GRAS processes.
HBW Insight - February 2, 2026
What’s Next? Five Things To Look Out For In February
Generics Bulletin previews the most noteworthy and anticipated events for February 2026.
Generics Bulletin - February 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for February 2026.
Generics Bulletin - February 1, 2026
Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026